Amano T, Koshida K, Nakajima K, Naito K, Hisazumi H
Hinyokika Kiyo. 1985 Dec;31(12):2107-11.
PPA, PHA and Su-PS skin tests were performed on 152 urogenital malignancy patients and the results obtained were analysed in terms of clinical course. The survival rate of 86 patients showing a positive response to the PPD skin test was significantly higher (P less than 0.005) than that of 65 patients showing a negative response to the PPD skin test. Among the 33 renal tumor patients, the positive rate of the 10 patients with stage I tumors to PPD skin test was significantly higher (P less than 0.05) than that of the 13 patients with stage IV tumors. In 68 bladder tumor patients, the response rate to PPD skin test in 47 patients with a low stage tumor was significantly high (P less than 0.05) compared with that in 21 patients with a high stage tumor. Out of 47 patients who died during the 84-month observation period, 10 (21.7%) and 3 (13.3%) showed a response change from negative to positive, in the PPD test and Su-PS test, respectively. It was assumed that 32 of the 46 patients (69.6%), 4 of the 6 patients (66.7%) and 17 of the 23 patients (73.9%) submitted to the PPD, PHA and Su-PS tests, respectively, showed a negative response at the time of their death.
对152例泌尿生殖系统恶性肿瘤患者进行了PPA、PHA和Su - PS皮肤试验，并根据临床病程对所得结果进行了分析。86例对PPD皮肤试验呈阳性反应的患者的生存率显著高于（P < 0.005）65例对PPD皮肤试验呈阴性反应的患者。在33例肾肿瘤患者中，10例I期肿瘤患者对PPD皮肤试验的阳性率显著高于（P < 0.05）13例IV期肿瘤患者。在68例膀胱肿瘤患者中，47例低分期肿瘤患者对PPD皮肤试验的反应率显著高于（P < 0.05）21例高分期肿瘤患者。在84个月观察期内死亡的47例患者中，分别有10例（21.7%）和3例（13.3%）在PPD试验和Su - PS试验中显示反应从阴性变为阳性。据推测，分别接受PPD、PHA和Su - PS试验的46例患者中的32例（69.6%）、6例患者中的4例（66.7%）和23例患者中的17例（73.9%）在死亡时呈阴性反应。
